Look for:

Our offer for

ADDEX THERAPEUTICS LIMITED SPON ADS EACH REP 120 ORD


ISIN:
US00654J2069
WKN:
00654J206

2024/03/27 21:30:00
Price
12.35 USD
Difference 2.49% (0.30)

General attributes

ISINUS00654J2069
SymbolADXN
ExchangeNasdaq
CurrencyUSD
SectorChemical / Pharmaceutical / Health
Security typeStock
Market cap (m)12 EUR
BenchmarkSWISS MARKET INDEX

Market data

Bid (Bid size)11.95 USD (900)
Ask (Ask size)12.95 USD (500)
Open12.35 USD
High12.7961 USD
Low11.63 USD
Close (prev. day)12.05 USD
VWAP12.354546 USD
Volume (pcs)4,212
Trading volume52,155.89
Number of trades148
Last size-

Futures and Options

Related Futures-
Related Options-

PDF Downloads

Company report: ADDEX THERAPEUTICS LIMITED SPON ADS EACH REP 120 ORDPDF Download

Scale: ABS REL         Instrument

Add Benchmark:



Information about previous performance does not guarantee future performance.
Source: FactSet

Recent research



2024/03/27 21:30:00
Price
12.35 USD
Difference 2.49% (0.30)

General attributes

ISINUS00654J2069
SymbolADXN
ExchangeNasdaq
CurrencyUSD
SectorChemical / Pharmaceutical / Health
Security typeStock
Market cap (m)12 EUR
BenchmarkSWISS MARKET INDEX

Market data

Bid (Bid size)11.95 USD (900)
Ask (Ask size)12.95 USD (500)
Open12.35 USD
High12.7961 USD
Low11.63 USD
Close (prev. day)12.05 USD
VWAP12.354546 USD
Volume (pcs)4,212
Trading volume52,155.89
Number of trades148
Last size-

Performance and Risk

6m1Y3Y
Perf (%)+3,479.71%+1,043.52%+17.62%
Perf (abs.)+12.01+11.27+1.85
Beta-1.13-0.740.64
Volatility438.63316.68206.58
Scale: ABS REL         Instrument

Add Benchmark:



Information about previous performance does not guarantee future performance.
Source: FactSet

Price data

Ø price 5 days | Ø volume 5 days (pcs.)12.00 USD (4,226)
Ø price 30 days | Ø volume 30 days (pcs.)10.81 USD (6,878)
Ø price 100 days | Ø volume 100 days (pcs.)8.12 USD (9,439)
Ø price 250 days | Ø volume 250 days (pcs.)3.75 USD (149,565)
YTD High | date13.50 USD (2024/01/29)
YTD Low | date5.90 USD (2024/01/02)
52 Weeks High | date13.50 USD (2024/01/29)
52 Weeks Low | date0.33 USD (2023/10/04)

All listings for ADDEX THERAPEUTICS LIMITED SPON ADS EACH REP 120 ORD

Exchange  DateTimePriceTrading volume (mio.)Number of trades
Stuttgart2024/03/2812:5710.90 EUR0.004
Nasdaq2024/03/2721:3012.35 USD0.05148
Munich2024/03/2808:1611.30 EUR0.001
Frankfurt2024/03/2809:5910.80 EUR0.003
Berlin2024/03/2813:0511.50 EUR0.006

Company Logo

https://gateway.mdgms.com/extern/logo_image.html?ID_LOGO=19965&ID_TYPE_IMAGE_LOGO=2

Contact Details

ADDEX THERAPEUTICS LTD.
- -
9, Chemin des Mines, Plan-les-Ouates - 1202 Genf
Telefon: +41-22-884-15-55
Fax: +41-22-884-15-56
E-mail: info@addextherapeutics.com

PDF Downloads

Company report: ADDEX THERAPEUTICS LIMITED SPON ADS EACH REP 120 ORDPDF Download

Company Profile

Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. It develops novel, orally available, and small molecule allosteric modulators for neurological disorders. Its pipeline includes Dipraglurant, ADX71149, GABAB PAM, mGlu7 NAM, mGlu2 NAM, mGlu4 PAM, and mGlu3 PAM. The company was founded by Vincent Mutel, Timothy Dyer, and Mark Epping-Jordan in 2002 and is headquartered in Geneva, Switzerland.

Members of Management Board

Tim DyerChairman of Managing Board
Jean-Philippe RocherMember of Executive Committee
Mikhail KalinichevMember of Executive Committee
Robert LütjensMember of Executive Committee
Roger G. MillsMember of Executive Committee

Board of directors

Isaac MankeMember of the administrative board
Raymond HillMember of the administrative board
Roger MillsMember of the administrative board
Jake NunnMember of the administrative board
Vincent LawtonChairman of the administrative boar





Decline
Accept

We use cookies and web analysis software to give you the best possible experience on our website. If you consent, these tools will be used. Please read more information here

INFORMATION FOR PRIVATE CLIENTS / CONSUMERS

Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.

By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer